PHS
PFM Health Sciences Portfolio holdings
AUM
$1.15B
This Quarter Return
+6.98%
1 Year Return
+21.39%
3 Year Return
+130.75%
5 Year Return
+265.32%
10 Year Return
+1,236.5%
AUM
$2.87B
AUM Growth
+$2.87B
(-6.9%)
Cap. Flow
-$228M
Cap. Flow
% of AUM
-7.95%
Top 10 Holdings %
Top 10 Hldgs %
36.49%
Holding
88
New
9
Increased
10
Reduced
24
Closed
13
Top Buys
| 1 |
Pfizer
PFE
|
$79.3M |
| 2 |
iRhythm Technologies
IRTC
|
$61.7M |
| 3 |
Johnson & Johnson
JNJ
|
$55.6M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
$41.1M |
| 5 |
Cardinal Health
CAH
|
$32.9M |
Top Sells
| 1 |
Eli Lilly
LLY
|
$62.6M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$50.6M |
| 3 |
HCA Healthcare
HCA
|
$50.1M |
| 4 |
Gilead Sciences
GILD
|
$42.8M |
| 5 |
McKesson
MCK
|
$42.8M |
Sector Composition
| 1 | Healthcare | 96.34% |
| 2 | Financials | 0.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Arcus Biosciences
RCUS
$1.13B
| $139M | 4.73% | 3,431,010 | – | – |
|
2
Outset Medical
OM
$247M
| $136M | 4.61% | 2,940,255 -26,457 | -0.9% | -$1.22M |
|
3
AbbVie
ABBV
$372B
| $124M | 4.23% | 916,496 | – | – |
|
|
HZNP
4
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $118M | 4.01% | 1,091,840 -469,450 | -30% | -$50.6M |
|
5
Cytokinetics
CYTK
$4.23B
| $112M | 3.83% | 2,465,016 -694,685 | -22% | -$31.7M |
|
6
Centene
CNC
$14.3B
| $91.7M | 3.12% | 1,112,480 +127,609 | +13% | +$10.5M |
|
7
Avantor
AVTR
$9.18B
| $87.6M | 2.98% | 2,079,657 | – | – |
|
|
8
Eli Lilly
LLY
$657B
| $82.5M | 2.81% | 298,643 -226,812 | -43% | -$62.6M |
|
|
9
Pfizer
PFE
$141B
| $79.3M | 2.7% | +1,343,384 | New | +$79.3M |
|
10
Erasca
ERAS
$445M
| $77M | 2.62% | 5,191,405 | – | – |
|
11
IQVIA
IQV
$32.4B
| $67.2M | 2.29% | 238,039 -119,877 | -33% | -$33.8M |
|
12
Humana
HUM
$36.5B
| $64.7M | 2.2% | 139,420 | – | – |
|
|
13
iRhythm Technologies
IRTC
$5.46B
| $61.7M | 2.1% | +523,982 | New | +$61.7M |
|
14
Universal Health Services
UHS
$11.6B
| $61.6M | 2.1% | 475,340 -45,446 | -9% | -$5.89M |
|
15
Caribou Biosciences
CRBU
$174M
| $59.4M | 2.02% | 4,092,309 | – | – |
|
16
Danaher
DHR
$147B
| $57.8M | 1.97% | 175,690 | – | – |
|
17
UnitedHealth
UNH
$281B
| $56M | 1.91% | 111,554 -33,741 | -23% | -$16.9M |
|
18
Myriad Genetics
MYGN
$593M
| $55.9M | 1.9% | 2,025,681 -847,237 | -29% | -$23.4M |
|
|
19
Johnson & Johnson
JNJ
$427B
| $55.6M | 1.89% | +324,972 | New | +$55.6M |
|
20
Dynavax Technologies
DVAX
$1.19B
| $53.5M | 1.82% | 3,805,370 +521,800 | +16% | +$7.34M |
|
21
ICU Medical
ICUI
$3.15B
| $52.4M | 1.78% | 220,587 | – | – |
|
22
Penumbra
PEN
$10.6B
| $50.9M | 1.73% | 177,088 | – | – |
|
|
23
HCA Healthcare
HCA
$94.5B
| $50.3M | 1.71% | 195,621 -194,886 | -50% | -$50.1M |
|
24
Icon
ICLR
$13.8B
| $49M | 1.67% | 158,183 | – | – |
|
25
Edwards Lifesciences
EW
$47.8B
| $48.4M | 1.65% | 373,492 -139,513 | -27% | -$18.1M |
|